Investigational varicella vaccine_Lot 1

Phase 3

GSK plc (GSK)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

GSKPhase 3$100.5B

Investigational varicella vaccine_Lot 1 Phase 3 Est. Readout

Investigational varicella vaccine_Lot 1• Chickenpox1,840

Dec 2026~Estimated

CT.gov

00%

Competitive Landscape

0 competitors in Chickenpox

View Full Landscape

Drug Information

Target Indication

Chickenpox

Clinical Trial

NCT06740630

Last updated: 10/27/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

GSK

GSK plc

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

Combined Hepatitis A and B vaccinePhase 3

Hepatitis B

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3

Infections, Meningococcal

62.5/25mcgPhase 3

Pulmonary Disease, Chronic Obstructive

FluoridePhase 3

Dental Caries

Haemophilus influenzae type b- and meningococcal (vaccine)Phase 3

Haemophilus Influenzae Type b

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts